KPRX

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Wall Street analysts forecast KPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPRX is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kiora Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Kiora Pharmaceuticals Inc. EPS for the last quarter amounts to 0.01 USD, decreased -101.23 % YoY.

Kiora Pharmaceuticals Inc (KPRX) has 12 emplpoyees as of December 15 2025.

Today KPRX has the market capitalization of 7.85M USD.